Novo Nordisk, Canada
Health Canada approves Novo Nordisk’s Wegovy to cut heart attacks
Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, marking it as the first treatment in the country authorised to assist in chronic weight management and to reduce the risk of non-fatal myocardial infarction (MI) in adults with a body mass index (BMI) of 27 kg/m² or greater, who have established cardiovascular disease.
Wall Street Journal on MSN1d
Novo Nordisk Says White House Obesity Plan Is Step in Right DirectionNovo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned ...
The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and ...
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...
A dose of four Wegovy injections will cost 1,400 yuan ($194), a fraction of the drug’s U.S. price, according to the Chinese ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
COPENHAGEN (Reuters) -Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback